scholarly journals A Japanese Encephalitis Virus Peptide Present on Johnson Grass Mosaic Virus-Like Particles Induces Virus-Neutralizing Antibodies and Protects Mice against Lethal Challenge

2003 ◽  
Vol 77 (6) ◽  
pp. 3487-3494 ◽  
Author(s):  
Manisha Saini ◽  
Sudhanshu Vrati
Keyword(s):  
Japanese Encephalitis Virus ◽  
Mosaic Virus ◽  
Japanese Encephalitis ◽  
Neutralizing Antibodies ◽  
Recombinant Dna ◽  
Gradient Centrifugation ◽  
Encephalitis Virus ◽  
Virus Like Particles ◽  
E Protein ◽  
Johnson Grass

ABSTRACT Protection against Japanese encephalitis virus (JEV) is antibody dependent, and neutralizing antibodies alone are sufficient to impart protection. Thus, we are aiming to develop a peptide-based vaccine against JEV by identifying JEV peptide sequences that could induce virus-neutralizing antibodies. Previously, we have synthesized large amounts of Johnson grass mosaic virus (JGMV) coat protein (CP) in Escherichia coli and have shown that it autoassembled to form virus-like particles (VLPs). The envelope (E) protein of JEV contains the virus-neutralization epitopes. Four peptides from different locations within JEV E protein were chosen, and these were fused to JGMV CP by recombinant DNA methods. The fusion protein autoassembled to form VLPs that could be purified by sucrose gradient centrifugation. Immunization of mice with the recombinant VLPs containing JEV peptide sequences induced anti-peptide and anti-JEV antibodies. A 27-amino-acid peptide containing amino acids 373 to 399 from JEV E protein, present on JGMV VLPs, induced virus-neutralizing antibodies. Importantly, these antibodies were obtained without the use of an adjuvant. The immunized mice showed significant protection against a lethal JEV challenge.

scholarly journals A Novel Recombinant Virus-Like Particles Displaying B and T Cell Epitopes of Japanese Encephalitis Virus Offers Protective Immunity in Mice and Guinea Pigs

Vaccines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 980
Author(s):  
Muhammad Naveed Anwar ◽  
Chunying Jiang ◽  
Di Di ◽  
Junjie Zhang ◽  
Shuang Guo ◽  
...  
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Guinea Pigs ◽  
Neutralizing Antibodies ◽  
Protective Immunity ◽  
Vaccine Development ◽  
Amino Acid Sequences ◽  
Encephalitis Virus ◽  
Potential Candidate ◽  
Virus Like Particles

Virus-like particles (VLPs) are non-replicative vectors for the delivery of heterologous epitopes and are considered one of the most potent inducers of cellular and humoral immune responses in mice and guinea pigs. In the present study, VLP-JEVe was constructed by the insertion of six Japanese encephalitis virus (JEV) envelope protein epitopes into different surface loop regions of PPV VP2 by the substitution of specific amino acid sequences without altering the assembly of the virus; subsequently, the protective efficacy of this VLP-JEVe was evaluated against JEV challenge in mice and guinea pigs. Mice immunized with the VLP-JEVe antigen developed high titers of neutralizing antibodies and 100% protection against lethal JEV challenge. The neutralizing and hemagglutination inhibition (HI) antibody responses were also induced in guinea pigs vaccinated with VLP-JEVe. In addition, immunization with VLP-JEVe in mice induced effective neutralizing antibodies and protective immunity against PPV (porcine parvovirus) challenge in guinea pigs. These studies suggest that VLP-JEVe produced as described here could be a potential candidate for vaccine development.

scholarly journals Stable High-Producer Cell Clone Expressing Virus-Like Particles of the Japanese Encephalitis Virus E Protein for a Second-Generation Subunit Vaccine

2003 ◽  
Vol 77 (16) ◽  
pp. 8745-8755 ◽  
Author(s):  
Asato Kojima ◽  
Atsushi Yasuda ◽  
Hideki Asanuma ◽  
Toyokazu Ishikawa ◽  
Akihisa Takamizawa ◽  
...  
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Neutralizing Antibodies ◽  
Second Generation ◽  
Cell Clone ◽  
Encephalitis Virus ◽  
Rabbit Kidney ◽  
Enzyme Linked Immunosorbent Assay ◽  
Dilution Method ◽  
Virus Like Particles

ABSTRACT We produced and characterized a cell clone (J12#26 cells) that stably expresses Japanese encephalitis virus (JEV) cDNA, J12, which encodes the viral signal peptide, premembrane (prM), and envelope (E) proteins (amino acid positions 105 to 794). Rabbit kidney-derived RK13 cells were transfected with a J12 expression plasmid, selected by resistance to marker antibiotics, and cloned by two cycles of a limiting-dilution method in the presence of antibiotics, a procedure that prevents the successful generation of E-producing cell clones. J12#26 cells secreted virus-like particles containing the authentic E antigen (E-VLP) into the culture medium in a huge enzyme-linked immunosorbent assay-equivalent amount (2.5 μg per 104 cells) to the internationally licensed JE vaccine JE-VAX. E-VLP production was stable after multiple cell passages and persisted over 1 year with 100% expressing cells without detectable cell fusion, apoptosis, or cell death, but was suspended when the cells grew to 100% confluency and contact inhibition occurred. Mice immunized with the purified J12#26 E-antigen without adjuvant developed high titers of neutralizing antibodies for at least 7 months and 100% protection against intraperitoneal challenge with 5 × 106 PFU of JEV when examined according to the JE vaccine standardization protocol. These results suggest that the recombinant E-VLP antigen produced by the J12#26 cell clone is an effective, safe, and low-cost second-generation subunit JE vaccine.

scholarly journals Preexisting Japanese Encephalitis Virus Neutralizing Antibodies and Increased Symptomatic Dengue Illness in a School-Based Cohort in Thailand

2011 ◽  
Vol 5 (10) ◽  
pp. e1311 ◽  
Author(s):  
Kathryn B. Anderson ◽  
Robert V. Gibbons ◽  
Stephen J. Thomas ◽  
Alan L. Rothman ◽  
Ananda Nisalak ◽  
...  
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Neutralizing Antibodies ◽  
Encephalitis Virus ◽  
School Based

scholarly journals A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs

2015 ◽  
Vol 9 (10) ◽  
pp. e0004081 ◽  
Author(s):  
Mélissanne de Wispelaere ◽  
Meret Ricklin ◽  
Philippe Souque ◽  
Marie-Pascale Frenkiel ◽  
Sylvie Paulous ◽  
...  
Keyword(s):  
Antibody Response ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Lentiviral Vector ◽  
Neutralizing Antibody ◽  
Encephalitis Virus ◽  
Virus Like Particles

scholarly journals Prevalence of Neutralizing Antibodies to Japanese Encephalitis Virus among High-Risk Age Groups in South Korea, 2010

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0147841 ◽  
Author(s):  
Eun Ju Lee ◽  
Go-Woon Cha ◽  
Young Ran Ju ◽  
Myung Guk Han ◽  
Won-Ja Lee ◽  
...  
Keyword(s):  
High Risk ◽  
South Korea ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Neutralizing Antibodies ◽  
Age Groups ◽  
Encephalitis Virus

scholarly journals Effects of the Japanese Encephalitis Virus Genotype V-Derived Sub-Viral Particles on the Immunogenicity of the Vaccine Characterized by a Novel Virus-Like Particle-Based Assay

Vaccines ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 81
Author(s):  
Sarah Honjo ◽  
Michiaki Masuda ◽  
Tomohiro Ishikawa
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Neutralizing Antibodies ◽  
Encephalitis Virus ◽  
Virus Genotype ◽  
Virus Like Particle ◽  
Viral Particles ◽  
Geographical Regions ◽  
Novel Virus ◽  
Genotype V

Japanese encephalitis virus (JEV) is classified into five genotypes labelled I through V. Although the genotype V (GV) JEV was originally found and had apparently been limited in Malaysia for more than 50 years, its emergence in Korea and China has recently been reported. Therefore, the GV JEV might be spreading over new geographical regions as a cause of potential public health problems. However, it is unknown whether the currently available JEV vaccines are effective against the emerging GV strains. To investigate this issue, a novel virus-like particle-based neutralizing assay was developed in this study. By using this assay, the inactivated JEV vaccine used in Japan and the recombinant sub-viral particles (SVPs) bearing the E protein of the GV Muar strain were characterized for the immunogenicity against the GV JEV. Although the inactivated vaccine alone failed to elicit a detectable level of neutralizing antibodies against the GV JEV, the vaccine added with the Muar-derived SVPs induced relatively high titers of neutralizing antibodies, associated with the efficient Th1 immune responses, against the GV JEV. The results indicate that addition of the GV JEV-derived antigens may be useful for developing the vaccine that is universally effective against JEV including the emerging GV strains.

Sign in / Sign up

Export Citation Format

Share Document